Real-world analysis compares risk of severe infection between treatments for multiple sclerosis, suggesting a safer option.
DRF-treated patients with MS had a significantly lower risk of SI compared with anti-CD20-treated patients, with no difference in ARR. More real-world studies are needed to understand the efficacy and safety of DMTs in the setting of de-escalation in aging patients with MS.
No takes yet. Share an insight, caveat, or question.
Obeidat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: